NTHI NTHI
Company Profile ↓Company Overview
NTHI (NTHI) is a publicly traded company listed on with a market capitalization of $76.97M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 26.0% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $39.99K (-51.8% YoY); net profit $-62.15M.
- Trailing 12 Months Year-on-year growth — revenue -51.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 26.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 25.98% |
| 1 Year: | -51.82% |
Stock Price Performance
| 1 Year: | -28.57% |
| 6 Months: | -62.77% |
| 3 Months: | -29.86% |
| 1 Month: | -19.54% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)39.51 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 26.0% over 5 years.
CONS
- Trading 71.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 43.00K | 20.00K | - | - | 39.99K | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | 31.94M | 5.71M | 6.93M | 13.63M | 7.01M |
| Operating Income | -1.55M | -1.28M | -2.20M | - | -31.90M | -5.71M | -6.93M | -13.63M | -7.01M |
| EBITDA | - | - | - | - | -32.02M | -5.61M | -7.73M | -14.25M | -7.81M |
| Interest Expense | - | - | - | - | 308.92K | 48.75K | 869.82K | 1.28M | 982.62K |
| Pretax Income | - | - | - | - | -32.33M | -5.68M | -8.62M | -15.52M | -8.82M |
| Tax Provision | - | - | - | - | - | - | - | - | - |
| Net Income | -2.94M | -4.52M | -2.18M | - | -32.33M | -5.68M | -8.62M | -15.52M | -8.82M |
| Diluted EPS | -0.18 | -0.27 | -0.12 | - | -1.78 | -0.30 | -0.45 | - | -0.38 |
| R&D Expense | 614.52K | 394.48K | 956.73K | - | 998.22K | 677.33K | 715.04K | - | 1.29M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 20.00K | 70.46K | 83.00K | 39.99K |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 2.86M | 8.17M | 7.23M | 58.21M |
| Operating Income | - | -2.84M | -8.10M | -7.14M | -58.17M |
| EBITDA | - | -2.85M | -12.20M | -9.10M | -59.61M |
| Interest Expense | - | 200.15K | 2.72M | 2.56M | 2.50M |
| Pretax Income | - | -3.05M | -14.92M | -11.90M | -62.15M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -3.05M | -14.92M | -11.90M | -62.15M |
| Diluted EPS | - | -0.16 | -0.80 | -0.63 | -3.20 |
| R&D Expense | - | - | - | 3.05M | 3.64M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 728.68K | 1.27M | 3.42M | 2.82M |
| Current Assets | - | 728.68K | 1.27M | 2.20M | 1.39M |
| Cash & Equivalents | - | 633.30K | 31.86K | 64.89K | 58.73K |
| Inventory | - | - | - | - | - |
| Receivables | - | - | - | - | - |
| Total Liabilities | - | 2.30M | 15.25M | 8.92M | 20.33M |
| Current Liabilities | - | 2.30M | 15.25M | 8.92M | 20.04M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 50.00K | 6.61M | 24.72K | 6.31M |
| Total Equity | - | -1.58M | -13.99M | -5.50M | -17.51M |
| Shares Outstanding | - | 18.75M | 18.75M | 18.75M | 21.99M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -881.74K | -1.88M | -4.21M | -20.36M |
| Investing Cash Flow | - | - | - | 0 | -500.00K |
| Financing Cash Flow | - | 1.49M | 1.28M | 4.25M | 20.86M |
| Capital Expenditure | - | - | - | - | -500.00K |
| Free Cash Flow | - | -881.74K | -1.88M | -4.21M | -20.86M |
| Net Change in Cash | - | 608.26K | -601.44K | 33.03K | -6.16K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | -14,188.0% | -11,492.2% | -8,605.4% | -145,459.4% |
| Net Margin % | - | -15,233.8% | -21,176.0% | -14,335.5% | -155,404.4% |
| ROE % | - | 193.4% | 106.7% | 216.1% | 355.0% |
| ROCE % | - | 180.1% | 57.9% | 129.7% | 337.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NTHI
After More Than a Decade Advising Large Organizations, Shomali Joins NeOnc Board - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQdGZ5UEpQc0FvbUluQlJxeWNmcHBrb3V3ZDhFeGg3RGRWRlpDUEctREtNTFFVbDZROWtWVUdTYnNpVmRhWnZndzZ5Q2hlaUVRLVhMZlFmZnNndUdtNU5ONTZONl9uYUJCaUZzREZmUko5OXhKU0pSYlNRLUVtcDJYbVNWYmlxQ3lqZ1JnN0…
NeOnc Technologies (NTHI) Could Be Targeting A Challenging Market With A Different Strategy - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPdzgxQk1Nb2I3Q2lpVjh0eWg5X0xERU1mVzJhSFM5VDdTT2FMaHJtZHduSzNTdzZCVFlvODhFaVpUQ2NWOEJQQzAzLTk0NUxVSUVFcW9Wc2lWV2QtekVpZUk5N09EYlg2M2VISmhnZkI5bG53aFFQN004N25CanlLb0R1UUNDUXMweFFEZl…
NeOnc Technologies Holdings, Inc. Revenue Breakdown – NASDAQ:NTHI - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE5pWXJER2U5RW9XT3E2YUtpWjdfOXBLTDVwblhZR3JhX1FJai1pRVFCaVd2NGlSVGFMdGJRQnlROE1PZzZfTmdEX21KdGNWRDdmRUdVeUxCMy13bUJtUUk4Ui1MeFhtckRDMXBqSHowdllrSHFJamM0?oc=5" target="_blank">NeOnc T…
NeOnc Technologies (NASDAQ:NTHI) Positioned for Potential Breakthrough in Brain Cancer Treatment Amidst Biotech Market Shift - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMi9gFBVV95cUxPTjF5OXpucG1QNFpDa19PeE8xa1JubEwzVDEyRF9wZXdFallLWUt6ZVdKazJ0aGMwcWdLSVY5OGhsN29UU1o3Rk1qZ00xWTQxaVNTMkxKTFJSTHRpTjJSREpTM2xWTHBidXlIeXAxckxOcmJxRUdFbEVqcGVKSkFucmEwMDZtTC1pNVRDTE…
NTHI|NeOnc Technologies Holdings Inc|Price:3.490| - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE5FVTZjc2I2enIzMU00RWhJanVOck91eHJrakIwM08tT3ExS3BiZmdKQkVOazhueTZLazdUVVFTaVRKcWN1WDFlRFlDNXdPM0lCWFlUeW1HMldtbkVoaTA2VHgyWjhjRGJ5MktNc3ln?oc=5" target="_blank">NTHI|NeOnc Technolo…
NTHI PE Ratio & Valuation, Is NTHI Overvalued - Intellectia AI
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE4xOVBoRjJQaTNpYWtSbTFqN3ZRcThILXF4bjZIb2h3RVVWekxBOEZVaW94ODZDbHZiQkhoNzg2QUY2MlNMZm1xNjRpQUNDcVpqQUxLZnJZZUdQUQ?oc=5" target="_blank">NTHI PE Ratio & Valuation, Is NTHI Overvalued…
NTHI — Frequently Asked Questions
What is the current share price of NTHI?
As of 2026-08-05 17:25 PDT, NTHI trades at $3.50 on NASDAQ/NYSE. Its 52-week range is $3.25 to $12.09.
What is the market capitalisation of NTHI?
NTHI has a market capitalisation of $76.97M on NASDAQ/NYSE.
What is the P/E ratio of NTHI?
NTHI trades at a trailing price-to-earnings (P/E) ratio of -1.09. Its price-to-book (P/B) ratio is -4.40.
Is NTHI a good stock to buy?
This page provides a data-driven analysis of NTHI, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.